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ABSTRACT 
hCG is a putative thyroid stimulator. The present studies were 
undertaken to examine its interaction and that of its desialylated 
variant asialo-hCG with recombinant human TSH (hTSH) receptor 
(hTSHr). To this end, we transfected a human thyroid carcinoma-cell 
line (HTC) lackina endoeenous TSHr with the full-leneth cDNA of 
the hTSHr. Unlike the wyld type, the transfected cells, t&med HTC- 
TSHr cells, were able to bind bovine TSH (bTSH) with high affinity 
and increase CAMP production in response to bTSH stimulation. Of 
the hCG forms, intact hCG displayed a weak activity to inhibit [iz51] 
bTSH binding to HTC-TSHr cells, with 100 mg/L (2.6 x 1Om6 mol/L) 
producing maximally a 20% inhibition, whereas asialo-hCG achieved 
half-maximum binding inhibition at a concentration of 8 mg/L (2.3 x 
lo-’ mol/L).The inhibitory constant (KJ of asialo-hCG for recombi- 
nant hTSHr was calculated from saturation experiments in the pres- 
ence of variable doses of bTSH and a fixed concentration of asialo- 
hCG to be approximately 8 X lo-’ mol/L. The interaction of asialo- 
hCG with TSHr was further assessed by studies of the direct binding 
of the radioactively labeled hormone to both HTC and HTC-TSHr 
cells. [iZ51]Asialo-hCG binding to HTC-TSHr cells was 4.7%, compared 
to 1.5% in the wild-twe cells lacking TSHr and was displaceable bv 
bTSH (0.1-100 IU/L); Indicating specific binding of the tracer to TSHr. 
Functionally, hCG (up to 100 mg/L; 2.6 X 1Om6 mol/L) proved unable 
to evoke any significant CAMP response over basal values in HTC- 
TSHr cells, as did asialo-hCG. Asialo-hCG, but not hCG, inhibited 
bTSH-stimulated adenylate cyclase activity in the cells in a dose- 
dependent manner. 
In conclusion, the present data show that intact hCG binds only 
weakly to HTC-TSHr-cells and produces no significant CAMP stimu- 
lation. which is at variance with data obtained in FRTL-5 and Chinese 
hamster ovary-TSHr cells, but in good accord with previous findings 
in human thyroid membranes. Asialo-hCG, on the other hand, strongly 
binds to recombinant TSHr and inhibits the CAMP resnonse to bTSH 
in HTC-TSHr cells, indicating that the desialylated hCG variant 
directly interacts with the receptor and truly is an antagonist of the 
hTSHr. (J Clin Endocrinol Metab 78: 933-938, 1994) 
E AND others have previously reported that hCG 
displayed a weak activity to inhibit the binding of [1251] 
bovine TSH ([1251]bTSH) to human thyroid membranes, but 
was unable to produce any significant stimulation of the 
CAMP response in such membrane preparations (1, 2). In 
other systems using thyroid tissue or cells of nonhuman 
origin, on the other hand, hCG has readily been identified 
as a thyroid stimulator of considerable potency (3-5). The 
failure to demonstrate a thyrotropic activity of hCG in human 
thyroid preparations in vitro may be due to species variations 
in the thyroid response to hCG or to a lack of sensitivity of 
the assay systems used. The affinity of hCG for TSH receptor 
(TSHr) can be enhanced by desialylation of the molecule, 
which transforms the hormone into a more potent agonist in 
FRTL-5 thyroid cells and a strong TSH antagonist in human 
thyroid membranes (6-9). 
Following the successful cloning of the human TSH 
(hTSH) receptor, it became possible to study both the direct 
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interaction of hCG with recombinant hTSHr and its func- 
tional consequences with respect to CAMP response (10, 11). 
In fact, Tomer et al. (12) recently reported that Chinese 
hamster ovary (CHO) cells transfected with hTSHr were 
stimulated by hCG to release CAMP. 
In view of the discrepant results that have been reported 
in human thyroid membranes and a recombinant hTSHr 
system, we undertook the present studies to examine the 
direct interaction of hCG and its desialylated variant form 
with recombinant hTSHr. To this end, we assessed their 
abilities to both inhibit [‘251]bTSH binding to a human thyroid 
carcinoma cell line (HTC) that lacked endogenous TSHr, but 
expressed the recombinant hTSHr, and to influence basal as 
well as bTSH-stimulated CAMP production in the cells. 
Materials and Methods 
Materials 
Labeled bTSH was kindly provided by Dr. V. Herzog (University of 
Bonn, Bonn, Germany) and the unlabeled hormone (-30 IU/mg) was 
purchased from Sigma (Deisenhofen, Germany). Crude urinary hCG 
(-2500 IlJ/mg) was obtained from Ayerst (Rouses Point, NY). 
For desialgation of hCG, immobilized neuraminidase from Clostri- 
dium aerfrinaens (tvne VI-A) was used (Sigma Chemical Co.). Cell culture 
reagents’ w&e purc’hased from GibcoyBRL (Eggenstein, Germany), “‘1 
from Behring (Marburg, Germany), and CAMP RIA kits from New 
England Nuclear-DuPont (Bad Homburg, Germany). 
The human thyroid cell line HTC derived from a follicular carcinoma 
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was kindly provided by Dr. Goretzki (University of Duesseldorf, Dues- 
seldorf, Germany) (13). hTSHr cDNA and the eukaryotic expression 
plasmid pSVZ-NEO-ECE employed for transfection of HTC cells were 
generous gifts from Dr. B. Rapoport (University of California-San Fran- 
cisco) (11). 
Preparation of hCG and asialo-hCG 
Highly purified hCG (-12,000 IU/mg) was isolated from crude hCG 
by sequential chromatography on columns of DEAE-52 and Sephadex 
G-100, as described previously, and was immunologically and biolog- 
ically indistinguishable from hCG CR 123 (NIH) (2). To obtain asialo- 
hCG, purified hCG was desialylated by digestion with neurarninidase 
following the protocol of van Hall et al. (14), which has been previously 
employed in our laboratory (2, 6, 9). Desialylation was more than 80% 
complete, as assessed by measuring sialic acid concentrations according 
to the colorimetric method of Warren (15) before and after the incubation 
with neuraminidase. 
Transfection of HTC cells 
hTSHr cDNA, inserted into EcoRI sites of the eukaryotic expression 
plasmid pSV2-NEO-ECE, was transfected into the human thyroid car- 
cinoma cell line HTC, which lacks endogenous TSHr, by the use of a 
modified lipofection method, as described previously (16-18). After 
selection of transfected cells by adding 400 mg/L Geneticin (GIBCO, 
Grand Island, NY) to the culture medium, a limiting dilution was 
performed to isolate distinct clones. Cells transfected with the plasmid 
without hTSHr cDNA served as negative controls. 
Cell cultures 
The transfected cells, termed HTC-TSHr cells, as well as the controls 
were routinely grown in 75-cm’ culture flasks in Coon’s modified Ham’s 
F-12 medium, supplemented with 10% fetal calf serum and five hor- 
mones or growth factors (10 rg/L glycyl-histidyl-lysine, 10 mg/L insulin, 
10 pg/L somatostatin, 5 mg/L transferrin, and 3.2 pg/L hydrocortisone) 
(17, 18). The cells were cultured in humidified 5% CO*-95% air, fed 
three times weekly, and passaged every 10 days. 
Radiolabeled ligand binding 
hCG was labeled with i2$I using a stoichiometric chloramine-T tech- 
nique and desialylated to obtain asialo-hCG tracer, as described previ- 
ously (2, 6, 9). To study radiolabeled ligand binding, cells were trans- 
ferred into 24-well plates (-lo4 cells/well). Incubation was conducted 
in the presence of approximately 8000 cpm [?]bTSH (SA, 40-60 mCi/ 
mg) or [‘251]asialo-hCG (30-40 mCi/mg) for 2 h at 37 C in Hanks’ 
Modified Buffer without NaCl, containing 0.25% BSA and 280 mmol/L 
sucrose (6, 17, 18). For inhibition experiments, the indicated amounts of 
unlabeled bTSH, hCG, and asialo-hCG, respectively, were added to- 
gether with the tracer. In addition, the saturation kinetics of bTSH 
binding were studied in the absence and presence of fixed concentrations 
of the putative inhibitors hCG or asiald-hCG. At the end of the incu- 
bation oeriod. cells were rinsed and solubilized with 1 mL 1 N NaOH, 
and radioactivity was determined in a y-counter. Nonspecific binding 
was measured in the presence of excess unlabeled ligand (10,000 IU/L 
bTSH) and subtracted to yield specific binding values. In addition to the 
bound/total (B/T) representation, data were analyzed by Scatchard 
plotting and computer-aided curve fitting with the Ligand program (19, 
20). 
manufacturer’s guidelines, and related to the protein content of the cells 
(17, 18). 
Statistical methods 
For statistical comparison of data, Wilcoxon’s test for unpaired obser- 
vations was used. 
Results 
Binding studies to HTC and HTC-TSHr cells 
HTC cells derived from a human thyroid follicular carci- 
noma apparently lacked the ability to express TSHr on their 
surface, as evidenced by specific [1251]bTSH binding ranging 
from 0.3-1.3%. After transfection of the cells with hTSHr 
cDNA, specific [‘251]bTSH binding markedly increased, ex- 
ceeding 6% in all experiments conducted. Nonspecific bind- 
ing was approximately 1% in both HTC and HTC-TSHr cells. 
Unlabeled bTSH inhibited tracer bound to HTC-TSHr cells 
in a dose-dependent manner, requiring a concentration of 
approximately 1 IU/L (1.2 X 10e9 mol/L) for half-maximum 
binding inhibition (Fig. 1). Of the hCG forms, intact hCG 
displayed little activity to inhibit [‘251]bTSH binding, with 
100 mg/L (2.6 X low6 mol/L) effecting only approximately 
20% inhibition. Asialo-hCG, on the other hand, proved 
much more potent in this respect, with only 8 mg/L (2.3 X 
10e7 mol/L) being required for half-maximum inhibition of 
[iz51]bTSH binding and 100 mg/L (2.9 X 1O-6 mol/L) pro- 
ducing nearly complete binding inhibition (Fig. 1). Asialo- 
hCG, when compared on the basis of molar concentrations 
effecting half-maximum inhibition of [‘251]bTSH binding 
(IDso), was calculated to be approximately 0.5% as potent as 
bTSH. Intact hCG could not be compared in this respect, 
because half-maximum binding inhibition of the tracer was 
6 
hCG 
Determination of cellulnr CAMP production 
Cells maintained in medium devoid of bTSH (H5 medium) for 5 days 
were incubated for 30 min at 37 C with 1 mmol/L 1-methvl-3-isobu- 
tylxanthine in the presence of various concentrations of bTSH, hCG, 
asialo-hCG, or a combination of bTSH and the hCG forms. After 
solubilization of the cells with ethanol, the intracellular CAMP concen- 
tration was measured by a commercially available RIA, according to the 
0.1 1 10 100 1000 
b’l’SH (IWL) 
hCG/Asialo-hCG (mgL) 
FIG. 1. Inhibition of the specific binding of [iZ51]bTSH to HTC-TSHr 
cells by bTSH, hCG, and asialo-hCG. Incubations were carried out for 
2 h at 37 C in Hanks’ Modified Buffer, as described in Materials and 
Methods. Each value represents the mean of closely concurring quad- 
ruplicate determinations. 
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not achieved with the highest dose used (Fig. 1). 
To further elucidate the mechanism of bTSH binding 
inhibition by the hCG forms, experiments were conducted 
to study the saturation kinetics of bTSH binding in the 
absence and presence of the inhibitor (Fig. 2). As indicated 
by Scatchard plotting and computer-assisted curve fitting of 
the data obtained with bTSH alone, two apparent binding 
sites for bTSH were present in HTC-TSHr cells, one of high 
affinity (-7 x 10-l’ mol/L) and relatively low capacity (B,,,, 
3 X lo-‘* mol/L; -1 fmo1/10,000 cells) and the other of 
lower affinity (-1 X 10m7 mol/L) and higher capacity (B,,,, 
9 X lo-*’ mol/L; -300 fmol/lO,OOO cells). The wild-type 
cells, on the other hand, exhibited only the low affinity TSH- 
binding sites, which are apparently unrelated to TSHr. 
Analysis of bTSH binding to HTC-TSHr cells in the presence 
of fixed concentrations (2 and 4 mg/L; -0.5 and 1 X low7 
mol/L) of hCG or asialo-hCG revealed the former to be 
inactive, but the latter to be a competitive inhibitor at the 
high affinity sites (Fig. 2). In another experiment, similar to 
the one depicted in Fig. 2, the concentration of hCG was 
increased to 66 mg/L (1.7 x 10V6 mol/L), which resulted in 
no significant change in the curve compared to the bTSH 
curve alone, and that of asialo-hCG to 8 mg/L (2.3 X 10P7 
mol/L), which resulted in a nearly complete ablation of high 
affinity bTSH binding. The calculated K, of asialo-hCG for 
recombinant TSHr was approximately 8 X lOwE mol/L. 
To further corroborate a direct interaction of asialo-hCG 
with recombinant TSHr, we performed direct binding studies 
with the radioactively labeled hormone to HTC and HTC- 
FIG. 2. Specific binding of [‘*‘I]bTSH to HTC-TSHr cells at variable 
doses of cold bTSH in the presence and absence of fixed concentrations 
of hCG or asialo-hCG. The incubation conditions were the same as 
those described in Fig.1. The inset shows the Scatchard plots of bTSH 
binding alone and bTSH binding in the presence of 4 mg/L asialo- 
hCG. The results indicate the presence of two apparent binding sites 
for bTSH (Kdi, 7.1 X 10-i” mol/L; Kd2, 1.1 X 10m7 mol/L; Bma,i, 3 x 
10-i’ mol/L or 1 fmol/lO,OOO cells; BmaxP, 9 x 10-l’ mol/L or 300 fmol/ 
10,000 cells) and a competitive inhibition of asialo-hCG at the high 
affinity binding sites in HTC-TSHr cells. For comparison, the wild- 
type cells (HTC cells) exhibited only the low affinity bTSH-binding 
sites. 
TSHr cells. Specific binding of [‘251]asialo-hCG was 4.7% to 
the transfected cells compared to 1.5% to the wild-type cells 
(P < 0.001, by Wilcoxon’s test; n = 4), and this binding could 
be inhibited in a dose-related manner by bTSH, indicating 
direct binding of the asialo-hCG tracer to TSHr (Fig. 3). 
CAMP production in HTC and HTC-TSHr cells 
bTSH stimulated intracellular CAMP production in HTC- 
TSHr cells in a dose-dependent fashion, and 10 IU/L bTSH 
increased basal CAMP levels approximately 9-fold (Fig. 4). A 
significant increase over basal values was observed at doses 
ranging between 0.05-0.1 IU/L bTSH, and half-maximum 
stimulation occurred at approximately 0.2-0.5 IU/L bTSH. 
In control cells, as expected from their negligible specific 
binding of [‘251]bTSH, CAMP production could not be signif- 
icantly augmented by bTSH in concentrations up to 100 IU/ 
L (data not shown). Unlike bTSH, both hCG and asialo- 
hCG, when added to the transfected cells in concentrations 
up to 100 mg/L (2.6 and 2.9 X 10e6 mol/L, respectively), 
were ineffective in significantly increasing basal CAMP pro- 
duction (Fig. 4). This was also true for the control cells (data 
not shown). 
Next, we examined the effect of hCG and its desialylated 
variant on bTSH-stimulated CAMP production in HTC-TSHr 
cells. In the presence of bTSH alone (0.5 IU/L), CAMP 
production was stimulated approximately 5-fold. Although 
the addition of intact hCG (up to 400 mg/L; 1.1 X 10P5 mol/ 
L) did not significantly affect the CAMP response to bTSH, 
asialo-hCG, added in increasing concentrations from 10 mg/ 
L (2.9 X 10m7 mol/L) to 200 mg/L (5.7 X 10m6 mol/L), showed 
a dose-dependent inhibition of bTSH-stimulated CAMP pro- 
duction (Fig. 5). The highest dose of asialo-hCG tested, 200 
mg/L (5.7 X 10m6 mol/L), was able to diminish by 90% the 
CAMP stimulation produced by 0.5 IU/L bTSH. When in- 
creasing the stimulatory bTSH concentration from 0.5 to 1 
IU/L, the inhibitory effect of asialo-hCG was observed to 
HTC-TSHr Cells 
-5 
“““. ““‘* . “.“‘* ‘“‘W 
0.01 0.1 1 10 100 
bTSH (IU/L) 
FIG. 3. Specific binding of [‘251]asialo-hCG to HTC and HTC-TSHr 
cells and its displacement by bTSH. 
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4. Stimulation of CAMP production in HTC-TSHr cells. After 
maintenance in H5 medium for 5 days, cells transfected with the hTSHr 
were incubated in the presence of 1 mmol/L 1-methyl-3-isobutylxan- 
thine with the indicated concentrations of bTSH, hCG, and asialo- 
hCG, respectively. Vertical bars indicate the mean + SD of quadruplicate 
determinations; the other points represent the means of closely con- 
curring duplicate determinations. 
loo - 
0 ; “““. . ““.‘. . ‘““* 
10 100 loo0 
Concentration (mg/L) 
FIG. 5. Effects of hCG and asialo-hCG on bTSH-stimulated CAMP 
production in HTC-TSHr cells. An approximately half-maximum stim- 
ulatory dose of bTSH (0.5 IU/L) was used in this experiment, and 
bTSH alone produced an approximately &fold stimulation of CAMP 
production, which was inhibited by the addition of asialo-hCG, but not 
hCG. Vertical bars indicate the mean + SD of quadruplicate determi- 
nations; the other points represent the means of closely concurring 
duplicate determinations. 
decrease (40% inhibition at 200 mg/L; 5.7 X 10e6 mol/L), 
indicating a competitive mode of action of the inhibitor. 
Discussion 
Interest in studies of the thyrotropic activity of hCG orig- 
inates from its putative roles as the thyroid stimulator re- 
sponsible for thyroid hyperfunction associated with tropho- 
blastic tumors and a regulator of maternal thyroid function 
during normal pregnancy (21-29). The question of whether 
hCG is indeed a thyroid stimulator of significant potency in 
man is, however, still discussed controversially, and evidence 
both in favor and against this view has been reported (30- 
35). In the present studies we have undertaken to investigate 
the interaction of hCG with recombinant hTSHr, exploring 
its ability to both inhibit the binding of [‘251]bTSH to the 
recombinant receptors and enhance CAMP production in cells 
expressing the recombinant receptors. To mimic human 
physiology as closely as possible, cloned hTSHr cDNA was 
transfected to and expressed in a human thyroid carcinoma 
cell line (HTC) that lacked endogenous TSHr, rather than in 
other systems, such as CHO cells. The HTC cells and its 
properties after transfection with the hTSHr cDNA have 
been described and characterized previously by our group 
and others (13, 17, 18). Particularly, HTC-TSHr cells have 
recently been demonstrated to retain the ability to synthesize 
thyroglobulin mRNA, which ascertains their descent from 
thyroid epithelium cells, and to express a functional TSHr 
coupled to the G, protein-adenylate cyclase complex, which 
is absent in the wild type (17). 
Purified hCG when incubated in increasing concentrations 
with [‘251]bTSH or added in a fixed concentration together 
with variable doses of cold bTSH displayed a weak activity 
to inhibit bTSH binding to HTC-TSHr cells, with 100 mg/L 
(2.6 X 10m6 mol/L) producing maximally a 20% inhibition. 
As for its functional effect, hCG in concentrations up to 100 
mg/L (2.6 X low6 mol/L) proved unable to evoke any signif- 
icant CAMP response over basal values in the cells, nor was 
it a meaningful inhibitor of bTSH-stimulated adenylate cy- 
clase activity. The absence of a functional response despite 
demonstration of weak TSH binding inhibiting activity may 
be explained by different dose requirements for the two 
effects or, more likely, occupancy by hCG of low affinity 
TSH-binding sites, which has been reported to be unrelated 
to TSHr and unaccompanied by a CAMP effect (36-38). 
These findings are entirely consistent with the data that have 
previously been reported using human thyroid membranes 
(1, 2). They are, however, at variance with our own data and 
the findings of others that have been obtained in FRTL-5 
and CHO-TSHr cells (4-6, 12, 39). Tomer et al. (12) and 
Yoshimura and co-workers (39), who studied expression of 
the hTSHr cDNA in CHO cells, showed a dose-related CAMP 
stimulation in response to purified hCG. With 9.6 X lop7 
mol/L hCG causing a definitive increase in CAMP and 100 
IU hCG producing a CAMP stimulation equivalent to 9.2 PU 
recombinant hTSH, as reported by these researchers, the 
thyroid-stimulating potency of hCG in CHO-TSHr cells re- 
sembled that previously calculated using FRTL-5 thyroid 
cells, but exceeded by far the thyrotropic activity of hCG 
displayed in human thyroid membranes (1, 4, 6, 12, 26, 39). 
Data regarding the binding of hCG to recombinant TSHr or 
the CHO cells themselves were not shown in these reports 
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(12, 39). 
The striking discrepancies in the thyrotropic activity of 
hCG depending on the assay system used are difficult to 
explain. Species variation in the thyroid response to hCG, 
similar to that observed with other thyroid stimulators, such 
as Graves’ immunoglobulins (40), could be one possible 
explanation, as has been suggested by some researchers (3). 
Further, FRTL-5 and CHO-TSHr cells appear to be generally 
more sensitive to stimulation by TSH than the HTC-TSHr 
cells used in the present work (4-6, 11, 12, 17, 39). In this 
respect, bTSH evoked a significant response in concentra- 
tions of 12.3-37 mIU/L in the CHO-TSHr cells used by 
Yoshimura et al. (39) compared to 50-100 mIU/L required 
in HTC-TSHr cells. However, even among CHO cell clones 
expressing the recombinant hTSHr, TSH sensitivity has been 
reported to vary widely (41). Apart from the fact that differ- 
ent TSH preparations and conditions were used for stimula- 
tion of these cells, the main difference between the cell lines 
expressing recombinant hTSHr is the number of receptors 
per cell. Whereas Rapoport’s (36) CHO-TSHr cells express 
approximately lo5 TSHr/cell, CHO-TSHr cells transfected 
by the group of Vassart (41,42) express between 2,000 (clone 
JP 26) and 90,000 (clone JP 09) receptors per cell. The HTC- 
TSHr cells used in the present studies express approximately 
2,300 receptors/cells, which is in the same range as that of 
human thyroid cells (17, 43). Thus, it is conceivable that the 
stimulatory effect of hCG on cAMP generation in CHO- 
TSHr cells may be at least in part due to a supraphysiological 
number of TSHr expressed by these cells (12, 39). 
Desialylation of the hCG molecule resulted in a marked 
increase in the affinity of the hormone to recombinant 
hTSHr, and asialo-hCG achieved a half-maximum inhibition 
of [1251]bTSH tracer binding at a concentration of 8 mg/L. Its 
inhibitory constant (Ki) was calculated to be approximately 8 
x 10m8 mol/L on the basis of analysis of saturation kinetics 
in the presence of variable doses of TSH and a fixed concen- 
tration of asialo-hCG. Furthermore, radioactively labeled 
asialo-hCG was shown to specifically bind to recombinant 
hTSHr, and this binding was displaceable by bTSH. Al- 
though desialylated hCG has long been known to interfere 
with various TSH actions in human thyroid membranes (2, 
7-9), this report adds strong evidence that asialo-hCG inter- 
acts directly with TSHr. Thus, asialo-hCG seems to be truly 
an antagonist of the hTSHr, because functionally it inhibited 
bTSH-stimulated adenylate cyclase activity, but was devoid 
of intrinsic activity in HTC-TSHr cells. Its mechanism of 
inhibition appears to be competitive in nature, as has been 
noted previously and demonstrated here again in its direct 
interaction with recombinant hTSHr (2, 7). Information on 
the interaction of desialylated hCG variants with hTSHr may 
be particularly relevant in the consideration of such sub- 
stances as possible TSH receptor blockers in the study and 
treatment of Graves’ disease. In this respect, asialo-hCG, 
owing to its short plasma half-life, would be available mainly 
for in vitro experiments, whereas other desialylated hCG 
variants, such as asialoagalacto-hCG, may be suitable for in 
vim use as an experimental TSHr blocker (9). 
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